Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for 24-months. Disease activity score in 28 joint...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/25785826.2019.1605036 |
| _version_ | 1818294260933328896 |
|---|---|
| author | Noriyoshi Ogawa Hiroyuki Ohashi Yasuhiro Ota Kaori Kobori Motohiro Suzuki Seiji Tsuboi Masakatsu Hayakawa Yoshinori Goto Taro Karahashi Osamu Kimoto Toshiaki Miyamoto Shogo Furukawa Kumiko Shimoyama Daisuke Suzuki Yuichiro Maekawa |
| author_facet | Noriyoshi Ogawa Hiroyuki Ohashi Yasuhiro Ota Kaori Kobori Motohiro Suzuki Seiji Tsuboi Masakatsu Hayakawa Yoshinori Goto Taro Karahashi Osamu Kimoto Toshiaki Miyamoto Shogo Furukawa Kumiko Shimoyama Daisuke Suzuki Yuichiro Maekawa |
| author_sort | Noriyoshi Ogawa |
| collection | DOAJ |
| description | The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for 24-months. Disease activity score in 28 joints (DAS28-CRP) was evaluated. Of 109 patients, 82 (75.2%) were on methotrexate (MTX; mean dosage 9.0 ± 2.7 mg/week); 48 (44.0%) were naive to biologics and 61 (56.0%) had failed biologics. The 1- and 2-year retention rates were 77% and 53%, respectively. At 24-months, the DAS28-CRP remission rates were 62.8% in the biologic-naïve patients, and 33.3% in the biologic-failure patients (p < .01), while the structural remission rates were 83.9% and 73.1%, respectively (p = .461). Abatacept was equally effective in RA patients who were and were not on concomitant MTX. Biologic-naïve was associated with better clinical outcome. Abatacept was effective in patients who showed decreasing anti-CCP antibody titers or serum MMP-3 levels during treatment. Infection was the most frequent adverse effect of abatacept therapy. In conclusion, abatacept is more effective in biologic-naïve than in biologic-failure RA patients with or without concomitant use of MTX. Abatacept is more effective in RA patients with than without decreasing serum MMP-3 or anti-CCP antibody titers during treatment. |
| first_indexed | 2024-12-13T03:28:56Z |
| format | Article |
| id | doaj.art-904c4137e93a417481af18a750bf9d09 |
| institution | Directory Open Access Journal |
| issn | 2578-5826 |
| language | English |
| last_indexed | 2024-12-13T03:28:56Z |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj.art-904c4137e93a417481af18a750bf9d092022-12-22T00:01:13ZengTaylor & Francis GroupImmunological Medicine2578-58262019-01-01421293810.1080/25785826.2019.16050361605036Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritisNoriyoshi Ogawa0Hiroyuki Ohashi1Yasuhiro Ota2Kaori Kobori3Motohiro Suzuki4Seiji Tsuboi5Masakatsu Hayakawa6Yoshinori Goto7Taro Karahashi8Osamu Kimoto9Toshiaki Miyamoto10Shogo Furukawa11Kumiko Shimoyama12Daisuke Suzuki13Yuichiro Maekawa14Hamamatsu University School of MedicineDepartment of Rheumatology, Omaezaki Municipal HospitalYasuhiro ClinicKobori Orthopedic ClinicHamamatsu University School of MedicineDepartment of Rheumatology, Shizuoka Kosei HospitalHayakawa ClinicGoto ClinicDepartment of Rheumatology, Fujieda Municipal HospitalKimoto ClinicDepartment of Rheumatology, Seirei Hamamatsu General HospitalHamamatsu University School of MedicineHamamatsu University School of MedicineHamamatsu University School of MedicineHamamatsu University School of MedicineThe aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for 24-months. Disease activity score in 28 joints (DAS28-CRP) was evaluated. Of 109 patients, 82 (75.2%) were on methotrexate (MTX; mean dosage 9.0 ± 2.7 mg/week); 48 (44.0%) were naive to biologics and 61 (56.0%) had failed biologics. The 1- and 2-year retention rates were 77% and 53%, respectively. At 24-months, the DAS28-CRP remission rates were 62.8% in the biologic-naïve patients, and 33.3% in the biologic-failure patients (p < .01), while the structural remission rates were 83.9% and 73.1%, respectively (p = .461). Abatacept was equally effective in RA patients who were and were not on concomitant MTX. Biologic-naïve was associated with better clinical outcome. Abatacept was effective in patients who showed decreasing anti-CCP antibody titers or serum MMP-3 levels during treatment. Infection was the most frequent adverse effect of abatacept therapy. In conclusion, abatacept is more effective in biologic-naïve than in biologic-failure RA patients with or without concomitant use of MTX. Abatacept is more effective in RA patients with than without decreasing serum MMP-3 or anti-CCP antibody titers during treatment.http://dx.doi.org/10.1080/25785826.2019.1605036rheumatoid arthritisabataceptcytokinesanti-citrullinated peptide antibody |
| spellingShingle | Noriyoshi Ogawa Hiroyuki Ohashi Yasuhiro Ota Kaori Kobori Motohiro Suzuki Seiji Tsuboi Masakatsu Hayakawa Yoshinori Goto Taro Karahashi Osamu Kimoto Toshiaki Miyamoto Shogo Furukawa Kumiko Shimoyama Daisuke Suzuki Yuichiro Maekawa Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis Immunological Medicine rheumatoid arthritis abatacept cytokines anti-citrullinated peptide antibody |
| title | Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis |
| title_full | Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis |
| title_fullStr | Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis |
| title_full_unstemmed | Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis |
| title_short | Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis |
| title_sort | multicenter observational clinical study of abatacept in japanese patients with rheumatoid arthritis |
| topic | rheumatoid arthritis abatacept cytokines anti-citrullinated peptide antibody |
| url | http://dx.doi.org/10.1080/25785826.2019.1605036 |
| work_keys_str_mv | AT noriyoshiogawa multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT hiroyukiohashi multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT yasuhiroota multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT kaorikobori multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT motohirosuzuki multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT seijitsuboi multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT masakatsuhayakawa multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT yoshinorigoto multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT tarokarahashi multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT osamukimoto multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT toshiakimiyamoto multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT shogofurukawa multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT kumikoshimoyama multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT daisukesuzuki multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis AT yuichiromaekawa multicenterobservationalclinicalstudyofabataceptinjapanesepatientswithrheumatoidarthritis |